Another Web

About Us

Pipeline

Press Releases

Location

Pipeline

Pipeline
JIN-NOVA Platform

JIN-NOVA Platform

AI and big data analysis hundreds of thousands of
patient genomic and clinical data records.

Prediction of therapeutic efficacy and toxicity and exploration of novel pipelines.

JIN-NOVA: AI Based Novel Drug Discovery Research Institute

Establishment of AI Based Novel Drug Discovery Research Institute in collaboration with DGIST (Daegu Gyeongbuk Institute of Science and Technology) in 2024.

Supercomputing system at DGIST

A total of 589 nodes
922 GPUs and 4.5 PB (petabytes) of storage
Capable of 2,358 trillion floating-point operations per second (TFLOPS)
Enablement of large-scale virtual screening of 450 million compound candidates as part of AI-driven novel drug discovery.
Enablement of the generation of optimal drug candidates by evaluating protein-ligand binding affinities using molecular dynamics simulations.

JIN-NOVA signs MOUs with collaborating institutions

Partners include Yonsei University, DGIST, KRICT, and KAIST.
J INTS BIO signed MOUs for AI-based novel drug development collaborations with research institutions and industry partners.
On the 4th, J INTS BIO held an MOU signing ceremony at Yonsei University’s Baekyangnuri Plaza in Seoul with Yonsei University College of Medicine (DaAn Cancer Research Lab), DGIST, and KAIST for AI-driven novel drug discovery collaboration.
The attendees included Wookje Cho, CEO of Yuhan Corporation, Sung-hoon Park, Deputy Floor Leader of the People Power Party, and Jung-ho Kim, Professor of Electrical and Electronic Engineering at KAIST.